Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
1.
J Appl Lab Med ; 2024 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-38574000

RESUMEN

BACKGROUND: Although low high-density lipoprotein cholesterol (HDL-C) levels are a common metabolic abnormality associated with insulin resistance, their role in cardiovascular risk stratification remains controversial. Recently, we developed a simple, high-throughput, cell-free assay system to evaluate the "cholesterol uptake capacity (CUC)" as a novel concept for HDL functionality. In this study, we assessed the CUC in patients with hypertriglyceridemia and diabetes mellitus. METHODS: The CUC was measured using cryopreserved serum samples from 285 patients who underwent coronary angiography or percutaneous coronary intervention between December 2014 and May 2019 at Kobe University Hospital. RESULTS: The CUC was significantly lower in diabetic patients (n = 125) than in nondiabetic patients (93.0 vs 100.7 arbitrary units (A.U.), P = 0.002). Patients with serum triglyceride (TG) levels >150 mg/dL (n = 94) also had a significantly lower CUC (91.8 vs 100.0 A.U., P = 0.004). Furthermore, the CUC showed a significant inverse correlation with TG, hemoglobin A1c (Hb A1c), homeostasis model assessment of insulin resistance (HOMA-IR), and body mass index (BMI). Finally, the HDL-C/Apolipoprotein A1 (ApoA1) ratio, calculated as a surrogate index of HDL particle size, was significantly positively correlated with the CUC (r2 = 0.49, P < 0.001), but inversely correlated with TG levels (r2 = -0.30, P < 0.001). CONCLUSIONS: The CUC decreased in patients with hypertriglyceridemia and diabetes mellitus, and HDL particle size was a factor defining the CUC and inversely correlated with TG levels, suggesting that impaired CUC in insulin-resistant states was partially due to the shift in HDL towards smaller particles. These findings provide a better understanding of the mechanisms underlying impaired HDL functionality.

2.
Sci Rep ; 13(1): 1899, 2023 02 02.
Artículo en Inglés | MEDLINE | ID: mdl-36732570

RESUMEN

High-density lipoprotein (HDL) cholesterol efflux capacity (CEC), which is a conventional metric of HDL function, has been associated with coronary heart disease risk. However, the CEC assay requires cultured cells and takes several days to perform. We previously established a cell-free assay to evaluate cholesterol uptake capacity (CUC) as a novel measure of HDL functionality and demonstrated its utility in coronary risk stratification. To apply this concept clinically, we developed a rapid and sensitive assay system based on a chemiluminescent magnetic particle immunoassay. The system is fully automated, providing high reproducibility. Measurement of CUC in serum is completed within 20 min per sample without HDL isolation, a notably higher throughput than that of the conventional CEC assay. CUC decreased with myeloperoxidase-mediated oxidation of HDL or in the presence of N-ethylmaleimide, an inhibitor of lecithin: cholesterol acyltransferase (LCAT), whereas CUC was enhanced by the addition of recombinant LCAT. Furthermore, CUC correlated with CEC even after being normalized by ApoA1 concentration and was significantly associated with the requirement for revascularization due to the recurrence of coronary lesions. Therefore, our new assay system shows potential for the accurate measurement of CUC in serum and permits assessing cardiovascular health.


Asunto(s)
Enfermedades Cardiovasculares , Lipoproteínas HDL , Humanos , Enfermedades Cardiovasculares/diagnóstico , Reproducibilidad de los Resultados , HDL-Colesterol , Inmunoensayo
3.
Circ J ; 87(6): 806-812, 2023 05 25.
Artículo en Inglés | MEDLINE | ID: mdl-36436874

RESUMEN

BACKGROUND: Recently, the function of high-density lipoprotein (HDL), rather than the HDL cholesterol (HDL-C) level, has been attracting more attention in risk prediction for coronary artery disease (CAD).Methods and Results: Patients with clinically diagnosed familial hypercholesterolemia (FH; n=108; male/female, 51/57) were assessed cross-sectionally. Serum cholesterol uptake capacity (CUC) levels were determined using our original cell-free assay. Linear regression was used to determine associations between CUC and clinical variables, including low-density lipoprotein cholesterol and the carotid plaque score. Multivariable logistic regression analysis was used to test factors associated with the presence of CAD. Among the 108 FH patients, 30 had CAD. CUC levels were significantly lower among patients with than without CAD (median [interquartile range] 119 [92-139] vs. 142 [121-165] arbitrary units [AU]; P=0.0004). In addition, CUC was significantly lower in patients with Achilles tendon thickness ≥9.0 mm than in those without Achilles tendon thickening (133 [110-157] vs. 142 [123-174] AU; P=0.047). Serum CUC levels were negatively correlated with the carotid plaque score (Spearman's r=0.37; P=0.00018). Serum CUC levels were significantly associated with CAD, after adjusting for other clinical variables (odds ratio=0.86, 95% CI=0.76-0.96, P=0.033), whereas HDL-C was not. CONCLUSIONS: HDL function, assessed by serum CUC level, rather than HDL-C level, adds risk stratification information among FH patients.


Asunto(s)
Enfermedades Cardiovasculares , Enfermedad de la Arteria Coronaria , Hiperlipoproteinemia Tipo II , Humanos , Masculino , Femenino , Lipoproteínas HDL , Enfermedades Cardiovasculares/complicaciones , Hiperlipoproteinemia Tipo II/diagnóstico , HDL-Colesterol
4.
Atherosclerosis ; 345: 44-50, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-35115159

RESUMEN

BACKGROUND AND AIMS: High-density lipoprotein (HDL) functionality is an important determinant of coronary artery disease (CAD) development. We recently developed cholesterol-uptake capacity (CUC), a rapid cell-free assay system that directly evaluates the capacity of HDL to accept additional cholesterol. We aimed to evaluate the association between CUC and revascularization in patients who have undergone percutaneous coronary intervention (PCI). METHODS: We retrospectively reviewed patients who underwent PCI with subsequent revascularization or coronary angiography (CAG) without revascularization. The patients who had frozen blood samples for which CUC were measurable at the index PCI and follow-up were enrolled. RESULTS: We finally enrolled 74 patients who underwent subsequent revascularization and 183 patients who underwent follow-up CAG without revascularization. The serum CUC level at the index PCI was significantly lower in the revascularization group than that in the non-revascularization group (84.3 [75.2-98.9] vs. 92.0 [81.6-103.3 A U.]; p = 0.004). Multivariate logistic regression analysis revealed that decreased serum CUC level at the index PCI was independently associated with subsequent revascularization (odds ratio, 0.98; 95% confidence interval, 0.969-1.000). After adjusting for 16 cardiovascular risk factors, the serum CUC level at the index PCI and follow-up and the absolute change in serum CUC level from the index PCI to follow-up were significantly lower in the revascularization group than those in the non-revascularization group. CONCLUSIONS: Serum CUC level at index PCI was independently associated with subsequent revascularization after PCI. Continuous assessment of HDL functionality by CUC might help predict subsequent revascularization after PCI.


Asunto(s)
Enfermedad de la Arteria Coronaria , Intervención Coronaria Percutánea , Colesterol , HDL-Colesterol , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Enfermedad de la Arteria Coronaria/terapia , Humanos , Lipoproteínas HDL , Intervención Coronaria Percutánea/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento
5.
Surg Endosc ; 36(6): 4181-4188, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-34580775

RESUMEN

BACKGROUND: Internal hernia (IH) is one of the critical complications after gastrectomy with Roux-en-Y reconstruction, which can be prevented by closing mesenteric defects. However, only few studies have investigated the incidence of IH after laparoscopic total gastrectomy (LTG) with Roux-en-Y reconstruction for gastric cancer till date. This study aimed to assess the efficacy of defect closure for the prevention of IH after LTG. METHODS: This multicenter, retrospective cohort study collected data from 714 gastric cancer patients who underwent LTG with Rou-en-Y reconstruction between 2010 and 2016 in 13 hospitals. We evaluated the incidence of postoperative IH by comparing closure and non-closure groups of Petersen's defect, jejunojejunostomy mesenteric defect, and transverse mesenteric defect. RESULTS: The closure group for Petersen's defect included 609 cases, while the non-closure group included 105 cases. The incidence of postoperative IH in the closure group for Petersen's defect was significantly lower than it was in the non-closure group (0.5% vs. 4.8%, p < 0.001). The closure group for jejunojejunostomy mesenteric defect included 641 cases, while the non-closure group included 73 cases. The incidence of postoperative IH in the closure group of jejunojejunostomy mesenteric defect was significantly lower than that in the non-closure group (0.8% vs. 4.1%, p = 0.004). Out of 714 patients, 41 underwent retro-colic reconstruction. No patients in the transverse mesenteric defect group developed IH. CONCLUSION: Mesenteric defect closure after LTG with Roux-en-Y reconstruction may reduce postoperative IH incidence. Endoscopic surgeons should take great care to prevent IH by closing mesenteric defects.


Asunto(s)
Derivación Gástrica , Hernia Abdominal , Laparoscopía , Obesidad Mórbida , Neoplasias Gástricas , Anastomosis en-Y de Roux/efectos adversos , Gastrectomía/efectos adversos , Derivación Gástrica/efectos adversos , Hernia Abdominal/cirugía , Humanos , Hernia Interna , Laparoscopía/efectos adversos , Obesidad Mórbida/cirugía , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/prevención & control , Estudios Retrospectivos , Neoplasias Gástricas/complicaciones , Neoplasias Gástricas/cirugía
6.
Nutrients ; 13(9)2021 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-34578988

RESUMEN

Recently we established a cell-free assay to evaluate "cholesterol uptake capacity (CUC)" as a novel concept for high-density lipoprotein (HDL) functionality and demonstrated the feasibility of CUC for coronary risk stratification, although its regulatory mechanism remains unclear. HDL fluidity affects cholesterol efflux, and trans fatty acids (TFA) reduce lipid membrane fluidity when incorporated into phospholipids (PL). This study aimed to clarify the effect of TFA in HDL-PL on CUC. Serum was collected from 264 patients after coronary angiography or percutaneous coronary intervention to measure CUC and elaidic acid levels in HDL-PL, and in vitro analysis using reconstituted HDL (rHDL) was used to determine the HDL-PL mechanism affecting CUC. CUC was positively associated with HDL-PL levels but negatively associated with the proportion of elaidic acid in HDL-PL (elaidic acid in HDL-PL/HDL-PL ratio). Increased elaidic acid-phosphatidylcholine (PC) content in rHDL exhibited no change in particle size or CUC compared to rHDL containing oleic acid in PC. Recombinant human lecithin-cholesterol acyltransferase (LCAT) enhanced CUC, and LCAT-dependent enhancement of CUC and LCAT-dependent cholesterol esterification were suppressed in rHDL containing elaidic acid in PC. Therefore, CUC is affected by HDL-PL concentration, HDL-PL acyl group composition, and LCAT-dependent cholesterol esterification. Elaidic acid precipitated an inhibition of cholesterol uptake and maturation of HDL; therefore, modulation of HDL-PL acyl groups could improve CUC.


Asunto(s)
Enfermedades Cardiovasculares/sangre , HDL-Colesterol/sangre , Ácidos Oléicos/fisiología , Anciano , Transporte Biológico , Biomarcadores/sangre , Femenino , Humanos , Masculino , Lípidos de la Membrana/sangre , Fosfatidilcolina-Esterol O-Aciltransferasa/sangre , Fosfatidilcolinas/sangre , Fosfolípidos/sangre , Sistema de Registros , Ácidos Grasos trans/sangre
7.
Medicine (Baltimore) ; 100(24): e26311, 2021 Jun 18.
Artículo en Inglés | MEDLINE | ID: mdl-34128870

RESUMEN

ABSTRACT: Pancreatectomy is an invasive surgery that is sometimes associated with complications. New-onset diabetes mellitus sometimes develops after partial pancreatectomy and severely affects the patient's quality of life. This study aimed to develop a preoperative prediction model of new-onset diabetes mellitus after partial pancreatectomy, which will help patients and surgeons to achieve more easily better common decisions on regarding whether to perform partial pancreatectomy. This retrospective cohort study analyzed medical records of patients who underwent partial pancreatectomy (total pancreatectomy excluded) from April 1, 2008, to February 28, 2016, which were available in the database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan). The predictors were preoperative age, body mass index, hemoglobin A1c level, blood glucose level, and indication for partial pancreatectomy. The outcome was the development of new-onset diabetes mellitus at 1 to 12 months after partial pancreatectomy. We used a logistic regression model and calculated the scores of each predictor. To determine test performance, we assessed discrimination ability using the receiver operating characteristic curve and calibration with a calibration plot and the Hosmer-Lemeshow test. We also performed internal validation using the bootstrap method. Of 681 patients, 125 (18.4%) had new-onset diabetes mellitus after partial pancreatectomy. The developed prediction model had a possible range of 0 to 46 points. The median score was 13, and the interquartile range was 9 to 22. The C-statistics of the receiver operating characteristic curve on the score to predict the outcome was .70 (95% confidence interval [CI], .65-.75). Regarding the test performance, the Hosmer-Lemeshow test was not significant (P = .17), and calibration was good. In the bootstrapped cohorts, the C-statistics was .69 (95% CI, .62-.76). We developed a preoperative prediction model for new-onset diabetes mellitus after partial pancreatectomy. This would provide important information for surgeons and patients when deciding whether to perform partial pancreatectomy.


Asunto(s)
Reglas de Decisión Clínica , Diabetes Mellitus/etiología , Pancreatectomía/efectos adversos , Complicaciones Posoperatorias/etiología , Medición de Riesgo/métodos , Anciano , Índice de Masa Corporal , Femenino , Hemoglobina Glucada/análisis , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Periodo Preoperatorio , Calidad de Vida , Curva ROC , Estudios Retrospectivos , Factores de Riesgo
8.
Updates Surg ; 72(3): 573-582, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32415666

RESUMEN

Many systematic reviews have been published to evaluate the clinical benefits of robotic surgery for gastric cancer. However, these reviews have investigated various outcomes and differ considerably in quality. In this overview, we summarize the findings and quality of these reviews. A comprehensive literature search was conducted using PubMed, Scopus, and the Cochrane Central Register of Controlled Trials to identify systematic reviews and meta-analyses that compared robotic surgery with laparoscopic surgery for gastric cancer. We summarized the results of the meta-analyses and evaluated the quality of the reviews using the AMSTAR-2 tool. The literature search identified 14 eligible reviews. The reviews showed that estimated blood loss was significantly less and time to resumption of oral intake was significantly shorter in patients who underwent robotic surgery than in those who underwent laparoscopic surgery. However, no significant differences in other outcomes were found between the two types of surgery. The quality of the included reviews was judged to be critically low. In conclusion, the available evidence, albeit of critically low quality, suggests that robotic surgery decreases estimated blood loss and shortens the time to resumption of oral intake in patients with gastric cancer. There is currently no high-quality evidence that robotic surgery has clinical benefits for gastric cancer patients.


Asunto(s)
Laparoscopía , Garantía de la Calidad de Atención de Salud/métodos , Calidad de la Atención de Salud , Procedimientos Quirúrgicos Robotizados , Neoplasias Gástricas/cirugía , Pérdida de Sangre Quirúrgica/estadística & datos numéricos , Ingestión de Alimentos , Humanos , Tempo Operativo , Resultado del Tratamiento
9.
Clin Chim Acta ; 503: 136-144, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31972150

RESUMEN

BACKGROUND: Cholesterol efflux from atherosclerotic lesion is a key function of high-density lipoprotein (HDL). Recently, we established a simple, high-throughput, cell-free assay to evaluate the capacity of HDL to accept additional cholesterol, which is herein referred to as "cholesterol uptake capacity (CUC)". OBJECTIVE: To clarify the cross-sectional relationship between CUC and coronary plaque properties. METHODS: We enrolled 135 patients to measure CUC and assess the morphological features of angiographic stenosis by optical coherence tomography (OCT). We estimated the extent of the lipid-rich plaque by multiplying the mean lipid arc by lipid length (lipid index). The extent of the OCT-detected macrophage accumulation in the target plaque was semi-quantitatively estimated using a grading system. RESULTS: Lipid-rich plaque lesions were identified in 125 patients (92.6%). CUC was inversely associated with the lipid index (R = -0.348, P < 0.0001). In addition, CUC was also inversely associated with macrophage score (R = -0.327, P < 0.0001). Conversely, neither circulating levels of HDL cholesterol nor apoA1 showed a similar relationship. CONCLUSIONS: We demonstrated that CUC was inversely related to lipid-rich plaque burden and the extent of macrophage accumulation, suggesting that CUC could be useful for cardiovascular risk stratification.


Asunto(s)
Colesterol/farmacocinética , Enfermedad de la Arteria Coronaria/patología , Lipoproteínas HDL/fisiología , Placa Aterosclerótica/patología , Anciano , Apolipoproteína A-I , HDL-Colesterol , Enfermedad de la Arteria Coronaria/metabolismo , Femenino , Humanos , Lípidos/análisis , Macrófagos/metabolismo , Masculino , Persona de Mediana Edad , Placa Aterosclerótica/metabolismo , Tomografía de Coherencia Óptica/métodos
10.
Surg Endosc ; 34(12): 5265-5273, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-31820152

RESUMEN

BACKGROUND: Presently, there is no consensus as to what procedure of intracorporeal esophagojejunostomy (EJS) in totally laparoscopic total gastrectomy (TLTG) is best to reduce postoperative complications. The aim of this study was to demonstrate the superiority of linear stapled reconstruction in terms of anastomotic-related complications for EJS in TLTG. METHODS: We collected data on 829 consecutive gastric cancer patients who underwent TLTG reconstructed by the Roux-en-Y method with radical lymphadenectomy between January 2010 and December 2016 in 13 hospitals. The patients were divided into two groups according to reconstruction method and matched by propensity score. Postoperative EJS-related complications were compared between the linear stapler (LS) and the circular stapler (CS) groups. RESULTS: After matching, data from 196 patients in each group were analyzed. The overall incidence of EJS-related complications was significantly lower in the LS group than in the CS group (4.1% vs. 11.7%, p = 0.008). The incidence of EJS anastomotic stenosis during the first year after surgery was significantly lower in the LS group than in the CS group (1.5% vs. 7.1%, p = 0.011). The incidence of EJS bleeding did not differ significantly between the groups, although no bleeding was observed in the LS group (0% vs. 2.0%, p = 0.123). The incidence of EJS leakage did not differ significantly between the groups (2.6% vs. 3.6%, p = 0.771). CONCLUSION: The use of linear stapled reconstruction is safer than the use of circular stapled reconstruction for intracorporeal EJS in TLTG because of its lower risks of stenosis.


Asunto(s)
Anastomosis Quirúrgica/métodos , Esofagoplastia/métodos , Gastrectomía/métodos , Laparoscopía/métodos , Puntaje de Propensión , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
11.
J Am Heart Assoc ; 8(9): e011975, 2019 05 07.
Artículo en Inglés | MEDLINE | ID: mdl-30995875

RESUMEN

Background We evaluated the importance of high-density lipoprotein (HDL) functionality for target-lesion revascularization in patients treated with coronary stents using a rapid cell-free assay system to evaluate the functional capacity of HDL to accept additional cholesterol (cholesterol-uptake capacity; CUC). Methods and Results From an optical coherence tomography (OCT) registry of patients treated with coronary stents, 207 patients were enrolled and their HDL was functionally evaluated by measuring the CUC. Follow-up OCT was performed (median duration, 24.5 months after stenting) to evaluate the presence of neoatherosclerosis. Clinical follow-up was performed to assess target-lesion revascularization for a median duration of 42.3 months after stent implantation. Neoatherosclerosis was identified in 37 patients (17.9%). Multivariate logistic regression analysis revealed that a decreased CUC was independently associated with neoatherosclerosis (odds ratio, 0.799; P<0.001). The CUC showed a significant inverse correlation with incidence of target-lesion revascularization (odds ratio, 0.887; P=0.003) and with lipid accumulation inside stents, suggesting that neoatherosclerosis contributes to the association between CUC and target-lesion revascularization. Conclusions Impaired HDL functionality, detected as decreased CUC, might lead to future stent failure by provoking atherogenic changes of the neointima within stents. Both quantitative and qualitative assessments of HDL might enable the improved prediction of clinical outcomes after stent implantation.


Asunto(s)
HDL-Colesterol/sangre , Enfermedad de la Arteria Coronaria/terapia , Vasos Coronarios/metabolismo , Macrófagos/metabolismo , Intervención Coronaria Percutánea/instrumentación , Placa Aterosclerótica , Stents , Anciano , Anciano de 80 o más Años , Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Vasos Coronarios/diagnóstico por imagen , Femenino , Humanos , Masculino , Persona de Mediana Edad , Intervención Coronaria Percutánea/efectos adversos , Sistema de Registros , Factores de Tiempo , Tomografía de Coherencia Óptica , Resultado del Tratamiento
12.
Int J Clin Oncol ; 24(1): 46-52, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30259217

RESUMEN

PURPOSE: Accurate diagnosis of lateral lymph node metastasis is a major concern in rectal cancer. Metastasis is not only a poor prognostic factor, but it can also affect decisions about treatment options, such as preoperative chemoradiotherapy and lateral lymph node dissection. The purpose of this review was to assess the diagnostic performance of magnetic resonance imaging and computed tomography for lateral lymph node metastasis in rectal cancer. METHODS: A literature search was systematically performed using PubMed, Scopus, and the Cochrane Central Register of Controlled Trials. All studies in which preoperative magnetic resonance imaging or computed tomography findings involving the lateral lymph nodes were compared with pathologic findings were included. Two authors independently assessed the literature and extracted the data, and any disagreement was resolved by discussion. Pooled sensitivity, specificity, and diagnostic odds ratios were estimated using hierarchical summary receiver-operating characteristic curve analysis. The methodologic quality of the included studies was assessed using the QUADAS-2 tool. RESULTS: Nine studies were included in the meta-analysis of magnetic resonance imaging. The pooled sensitivity, specificity, and diagnostic odds ratio for magnetic resonance imaging were 0.72 [95% confidence interval (CI) 0.66-0.78], 0.80 (95% CI 0.73-0.85), and 10.2 (95% CI 6.4-16.3), respectively. Pooled analyses were not conducted for computed tomography because of the small number of studies (only three could be identified) and the wide range in diagnostic performance between these studies. CONCLUSIONS: Magnetic resonance imaging was useful to diagnose lateral lymph node metastasis in rectal cancer, especially due to high specificity.


Asunto(s)
Ganglios Linfáticos/patología , Imagen por Resonancia Magnética/métodos , Neoplasias del Recto/diagnóstico por imagen , Neoplasias del Recto/diagnóstico , Tomografía Computarizada por Rayos X/métodos , Humanos , Metástasis Linfática , Curva ROC
13.
J Appl Lab Med ; 2(2): 186-200, 2017 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-32630971

RESUMEN

BACKGROUND: Recent studies have shown that the cholesterol efflux capacity of HDL is a better predictor of cardiovascular disease (CVD) than HDL cholesterol. However, the standard procedures used for measuring cholesterol efflux capacity involve radioisotope-labeled cholesterol and cultured macrophages. Thus, a simpler method to measure HDL functionality is needed for clinical application. METHODS: We established a cell-free assay system to evaluate the capacity of HDL to accept additional cholesterol, which we named cholesterol "uptake capacity," using fluorescently labeled cholesterol and an anti-apolipoprotein A1 antibody. We quantified cholesterol uptake capacity of apolipoprotein B (apoB)-depleted serum samples from patients with coronary artery disease who had previously undergone revascularization. RESULTS: This assay system exhibited high reproducibility (CV <10%) and a short processing time (<6 h). The myeloperoxidase-mediated oxidation of apoB-depleted serum impaired cholesterol uptake capacity. Cholesterol uptake capacity correlated significantly with cholesterol efflux capacity (r2 = 0.47, n = 30). Furthermore, cholesterol uptake capacity correlated inversely with the requirement for revascularization because of recurrence of coronary lesions in patients with optimal control of LDL cholesterol (P < 0.01, n = 156). A multivariate analysis adjusted for traditional coronary risk factors showed that only cholesterol uptake capacity remained significant (odds ratio, 0.48; 95% CI, 0.29-0.80; P = 0.0048). CONCLUSIONS: Cholesterol uptake capacity assay evaluates the functionality of HDL in a sensitive and high-throughput manner without using radioisotope label and cells. This assay system could be used for the assessment of CVD risk in the clinical settings.

14.
World J Gastroenterol ; 22(46): 10232-10241, 2016 Dec 14.
Artículo en Inglés | MEDLINE | ID: mdl-28028372

RESUMEN

AIM: To analyse the long-term prognostic impact of circulating tumour cells (CTCs) in gastric cancer patients who underwent surgery. METHODS: A 7.5-mL peripheral vein blood sample was obtained from each patient with treatment-negative gastric adenocarcinoma before surgery. OBP-401, a telomerase-specific, replication-selective, oncolytic adenoviral agent carrying the green fluorescent protein gene, was used to label CTCs. Correlations between the number of CTCs and clinical end points were evaluated. RESULTS: The median follow-up period of the surviving patients with gastric cancer was 60 mo. The CTC number tended to increase concomitantly with disease progression. The overall survival of patients with more than five CTCs in 7.5-mL of peripheral blood was lower than that of patients with five or less CTCs, although the difference was not significant (P = 0.183). A significant difference in relapse-free survival was found between patients with more than five and those with five or less CTCs (P = 0.034). CONCLUSION: A lower number of CTCs was correlated with higher relapse-free survival rates in patients. Detection of CTCs using OBP-401 may be useful for predicting prognosis in gastric cancer.


Asunto(s)
Adenocarcinoma/sangre , Células Neoplásicas Circulantes , Neoplasias Gástricas/sangre , Adenocarcinoma/mortalidad , Adenocarcinoma/terapia , Adulto , Anciano , Estudios de Casos y Controles , Quimioterapia Adyuvante , Supervivencia sin Enfermedad , Femenino , Gastrectomía , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias Gástricas/mortalidad , Neoplasias Gástricas/terapia
15.
Gastric Cancer ; 19(1): 287-92, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25503677

RESUMEN

BACKGROUND: Remnant gastric cancer is increasing with the earlier detection of gastric cancer and improved medical care. Laparoscopic gastrectomy for remnant gastric cancer has been reported sporadically in association with the increased use of minimally invasive techniques. However, because of the rarity of remnant gastric cancer, the number of cases reported per study has been small. We therefore reviewed all published English-language reports, including our experience, to better characterize the technical aspects of currently used procedures. METHODS: Ten patients who underwent laparoscopic gastrectomy for remnant cancer between August 2005 and March 2014 were retrospectively studied. A comprehensive literature search was performed using the PubMed database to identify English-language studies on laparoscopic gastrectomy for remnant gastric cancer that were published before May 2014. RESULTS: There was no conversion to open surgery. The mean operating time was 325 min, and mean intraoperative blood loss was 55 g. The mean number of retrieved lymph nodes was 22, and mean postoperative hospital stay was 13 days. There was only one minor wound infection (overall morbidity rate, 10%). From the literature review, all comparative studies revealed that laparoscopic gastrectomy for remnant gastric cancer required a longer operating time, and most studies reported less intraoperative blood loss, an equivalent number of harvested lymph nodes, and a shorter postoperative stay as compared with open surgery. CONCLUSION: Proficiency in advanced laparoscopic surgical techniques, such as proper adhesiolysis and stable laparoscopic anastomosis, will allow laparoscopic gastrectomy for remnant gastric cancer to be performed with satisfactory short-term results. This minimally invasive approach can be one treatment option for remnant gastric cancer.


Asunto(s)
Gastrectomía/métodos , Laparoscopía/métodos , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugía , Anciano , Anciano de 80 o más Años , Pérdida de Sangre Quirúrgica , Femenino , Muñón Gástrico/patología , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/cirugía , Tempo Operativo , Estudios Retrospectivos , Resultado del Tratamiento
16.
Nihon Geka Gakkai Zasshi ; 116(1): 45-9, 2015 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-25842813

RESUMEN

Several studies of minimally invasive esophagectomy (MIE) for esophagogastric junction (EGJ) tumors have been reported from Western countries with high incidences of lower esophageal cancer. Less invasiveness and a better quality of life after MIE compared with open esophagectomy were found in a randomized controlled trial in Europe. On the other hand, as laparoscopic total gastrectomy for upper gastric cancer has gradually become more common, laparoscopic transhiatal resection and reconstruction to treat EGJ tumors have been reported in Japan. Some potential benefits of laparoscopic total gastrectomy for upper gastric cancer, such as less blood loss and fewer complications, were indicated in comparative studies. Therefore, similar benefits are also expected for EGJ tumors, although there is no current evidence for this. It is difficult to determine which minimally invasive approach is better because the appropriate approach and extent of resection may differ depending on the location and size of each tumor. For the minimally invasive approach to the treatment of EGJ tumors to be accepted as an option, a safe reconstruction method with good long-term quality of life needs to be established.


Asunto(s)
Endoscopía Gastrointestinal/métodos , Neoplasias Esofágicas/cirugía , Esofagectomía/métodos , Unión Esofagogástrica/cirugía , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Neoplasias Gástricas/cirugía , Humanos , Laparoscopía , Calidad de Vida , Procedimientos de Cirugía Plástica/métodos
17.
Oncol Rep ; 32(5): 1772-8, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25176113

RESUMEN

We developed a detection method for circulating tumor cells (CTCs) using the telomerase-specific adenovirus OBP-401. This recombinant virus has a telomerase promoter at the 5'-end of the viral genome and GFP at the 3'-end. To date, CTC enumeration using OBP-401 has shown prognostic impact for gastric and small cell lung cancer patients. In the present study, peripheral blood samples from patients with eight types of cancer, including some cancers previously untested with OBP-401 (i.e., esophagus, pancreas, and prostate cancers) were subjected to this method in order to evaluate its versatility. It was recently discovered that some white blood cells (WBCs) false-positively react with OBP-401. Although anti-CD45 antibodies can absorb these adverse cells from peripheral blood, the simplicity of the OBP-401 method would be diminished by the introduction of antibody treatment. Therefore, we evaluated another approach to minimize the false positivity of WBCs. Seven anti-CD antibodies were employed to stain the species of WBCs that false-positively reacted with OBP-401. We revealed that the false-positively reacted WBCs were monocytes in the peripheral blood of both healthy subjects and cancer patients. Based on a size distribution analysis of the GFP-positive monocytes, the size criterion for CTCs using OBP-401 was defined to be a cellular diameter>8.4 µm. In total, 43% of 86 cancer patients examined in the present study were CTC-positive using this definition. CTCs were enumerated from peripheral blood samples collected from patients with each of the eight types of cancer; the detectability of CTCs for esophagus, pancreas and prostate cancers by the OBP-401 method was confirmed for the first time in the present study. However, no clear correlation between CTC positivity and the clinical characteristics of patients with any type of cancer was observed because of the small number of patients with each type of cancer. An additional clinical study will be conducted to confirm the clinical meaning of CTCs enumerated by OBP-401.


Asunto(s)
Adenoviridae/genética , Neoplasias/diagnóstico , Células Neoplásicas Circulantes/patología , Telomerasa , Adenoviridae/metabolismo , Anciano , Anciano de 80 o más Años , Anticuerpos/metabolismo , Antígenos CD/metabolismo , Pruebas Diagnósticas de Rutina/métodos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/sangre , Neoplasias/patología , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Reproducibilidad de los Resultados
18.
Oncol Lett ; 7(5): 1469-1473, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24765158

RESUMEN

The detection of circulating tumor cells (CTCs) in peripheral blood is currently an important field of study. Detection of CTCs by the OBP-401 assay (TelomeScan®) has previously been reported to be useful in the diagnosis, prognosis and evaluation of therapeutic efficacy in breast and gastric cancer. The aim of the present study was to evaluate the OBP-401 assay as a novel method of detecting CTCs of small cell lung cancer (SCLC) patients and to evaluate whether CTC count is associated with prognosis. Prospectively, 30 consecutively diagnosed SCLC patients who had commenced chemotherapy or chemoradiotherapy were enrolled as subjects of the current study. Peripheral blood specimens were collected from the SCLC patients prior to and following the initiation of treatment and the viable CTCs were detected in the specimens following incubation with a telomerase-specific, replication-selective, oncolytic adenoviral agent, which was carrying the green fluorescent protein gene. CTCs were detected in 29 patients (96%). The group of 21 patients with a CTC count of <2 cells/7.5 ml prior to treatment (baseline) had a significantly longer median survival time than the group of eight patients with a CTC count of ≥2 cells/7.5 ml prior to treatment (14.8 and 3.9 months, respectively; P=0.007). The results of a multivariate analysis showed that the baseline CTC count was an independent prognostic factor for survival time (hazard ratio, 3.91; P=0.026). Among the patients that achieved a partial response to treatment, patients who had a CTC count of <2 cells/7.5 ml following two cycles of chemotherapy tended to have a longer median progression-free survival compared with patients who had a CTC count of ≥2 cell/7.5 ml (8.3 and 3.8 months, respectively; P=0.07). Therefore, CTCs may be detected via OBP-401 assay in SCLC patients and the CTC count prior to treatment appears to be a strong prognostic factor.

19.
PLoS One ; 8(2): e56012, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23457492

RESUMEN

Catalase is a key antioxidant enzyme that catalyzes the decomposition of hydrogen peroxide (H2O2) to water and oxygen, and it appears to shuttle between the cytoplasm and peroxisome via unknown mechanisms. Valosin-containing protein (VCP) belongs to the AAA class of ATPases and is involved in diverse cellular functions, e.g. cell cycle and protein degradation, etc. Here we show that VCP and PEX19, a protein essential for peroxisome biogenesis, interact with each other. Knockdown of either VCP or PEX19 resulted in a predominantly cytoplasmic redistribution of catalase, and loss of VCP ATPase activity also increased its cytoplasmic redistribution. Moreover, VCP knockdown decreased intracellular ROS levels in normal and H2O2-treated cells, and an oxidation-resistant VCP impaired the ROS-induced cytoplasmic redistribution of catalase. These observations reveal a novel feedback mechanism, in which VCP can sense H2O2 levels, and regulates them by controlling the localization of catalase.


Asunto(s)
Adenosina Trifosfatasas/metabolismo , Catalasa/análisis , Catalasa/metabolismo , Proteínas de Ciclo Celular/metabolismo , Citoplasma/metabolismo , Peróxido de Hidrógeno/metabolismo , Proteínas de la Membrana/metabolismo , Adenosina Trifosfatasas/genética , Proteínas de Ciclo Celular/genética , Técnicas de Silenciamiento del Gen , Células HeLa , Humanos , Proteínas de la Membrana/genética , ARN Interferente Pequeño/genética , Especies Reactivas de Oxígeno/metabolismo , Regulación hacia Arriba , Proteína que Contiene Valosina
20.
BMC Cancer ; 12: 346, 2012 Aug 09.
Artículo en Inglés | MEDLINE | ID: mdl-22873704

RESUMEN

BACKGROUND: The identification of circulating tumour cells (CTCs) in peripheral blood is a useful approach to estimate prognosis, monitor disease progression, and measure treatment effects in various malignancies. However, clinical relevance of CTCs is controversial. We attempted to detect viable CTCs in the peripheral blood of gastric cancer patients using a telomerase-specific viral agent. METHODS: We took a 7.5-ml blood sample from 65 treatment-negative gastric cancer patients before surgery and 10 healthy volunteers. We detected viable CTCs in the blood samples after incubating them with a telomerase-specific, replication-selective, oncolytic adenoviral agent carrying the green fluorescent protein (GFP) gene (OBP-401). GFP-positive CTCs were defined as having a diameter of at least 7.735 µm; this threshold was determined by receiver operating characteristic curve analysis. GFP-positive cells were counted under a fluorescence microscope. RESULTS: There was a significant difference in overall survival among the patients with 0-4 and those with ≥5 GFP-positive CTCs in the stage I-IV disease group and stage II-IV advanced disease group. The number of GFP-positive CTCs was not related to cancer stage. Among the pathological findings, the number of GFP-positive CTCs was only significantly related to venous invasion, although there were trends towards more GFP-positive CTCs with disease progression (tumour depth, lymph node metastasis, distant metastasis, lymphatic invasion, and histological type). CONCLUSIONS: There was a significant relationship between the number of GFP-positive CTCs and overall survival in the patients with gastric cancer. The detection of CTCs using OBP-401 may be useful for prognostic evaluation. TRIAL REGISTRATION: University Hospital Medical Information Network in Japan, UMIN000002018.


Asunto(s)
Adenoviridae/genética , Células Neoplásicas Circulantes/patología , Virus Oncolíticos/genética , Neoplasias Gástricas/sangre , Telomerasa/metabolismo , Adenoviridae/metabolismo , Adulto , Anciano , Estudios de Casos y Controles , Femenino , Colorantes Fluorescentes/química , Proteínas Fluorescentes Verdes/química , Proteínas Fluorescentes Verdes/genética , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Virus Oncolíticos/metabolismo , Pronóstico , Estudios Prospectivos , Curva ROC , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/genética , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/patología , Neoplasias Gástricas/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...